BOOM
Citations are updated once a week. Recently added citations may not appear.
| Context | Citation |
|---|---|
| Saccharomyces cerevisiae var boulardii {S. boulardii} - unclassified Escherichia |
👶
Effect of Saccharomyces boulardii on Liver Diseases: A Systematic Review. Microorganisms (Microorganisms ) Vol: 12 Issue 8 Pages: Pub: 2024 Aug 15 Epub: 2024 Aug 15 Authors Maslennikov R , Benuni N , Levshina A , Adzhieva F , Demina T , Kucher A , Pervushova E , Yuryeva E , Poluektova E , Zolnikova O , Kozlov E , Sigidaev A , Ivashkin V , Html Article Publication |
| Saccharomyces cerevisiae var boulardii {S. boulardii} - unclassified Escherichia |
👶
Intervention with fructooligosaccharides, Saccharomyces boulardii, and their combination in a colitis mouse model. Frontiers in microbiology (Front Microbiol ) Vol: 15 Issue Pages: 1356365 Pub: 2024 Epub: 2024 May 21 Authors Wu Y , Fu H , Xu X , Jin H , Kao QJ , Teng WL , Wang B , Zhao G , Pi XE , Html Article Publication |
| Saccharomyces cerevisiae var boulardii {S. boulardii} - unclassified Escherichia |
👶
Effects of fructooligosaccharides and Saccharomyces boulardii on the compositional structure and metabolism of gut microbiota in students. Microbiological research (Microbiol Res ) Vol: 285 Issue Pages: 127741 Pub: 2024 Aug Epub: 2024 May 9 Authors Fu H , Chen Z , Teng W , Du Z , Zhang Y , Ye X , Yu Z , Zhang Y , Pi X , Publication |
| Saccharomyces cerevisiae var boulardii {S. boulardii} - unclassified Escherichia |
👶
Saccharomyces boulardii, a yeast probiotic, inhibits gut motility through upregulating intestinal serotonin transporter and modulating gut microbiota. Pharmacological research (Pharmacol Res ) Vol: 181 Issue Pages: 106291 Pub: 2022 Jul Epub: 2022 Jun 8 Authors Gu Y , Wang C , Qin X , Zhou B , Liu X , Liu T , Xie R , Liu J , Wang B , Cao H , Publication |
BOOM
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
